Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 2/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21572170 | 0.92 | KIT (0.34) | HPGD | |
| SCHEMBL20085209 | 0.84 | HPGD (0.39) | ALDH1A1MAPTHPGDLMNAMEN1 | |
| SCHEMBL20084030 | 0.84 | HPGD (0.31) | HPGD | |
| SCHEMBL20084140 | 0.84 | ALDH1A1 (0.34) | ALDH1A1MAPTHPGDLMNAXDH | |
| SCHEMBL21572151 | 0.83 | HPGD (0.30) | HPGD | |
| SCHEMBL21572157 | 0.81 | HPGD (0.31) | ALDH1A1HPGD | |
| SCHEMBL21572168 | 0.81 | NPSR1 (0.37) | ALDH1A1MAPTHPGDLMNAMEN1 | |
| SCHEMBL20084873 | 0.81 | HPGD (0.36) | ALDH1A1MAPTHPGDLMNAMEN1 | |
| SCHEMBL18332260 | 0.79 | ALOX5 (0.40) | ALDH1A1MAPTHPGDLMNAMEN1 | |
| SCHEMBL21572175 | 0.79 | HPGD (0.31) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312172-B1 | AMINOPYRAZOLE DERIVATIVES USEFUL AS SRC KINASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10479780-B2 | Aminopyrazole derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-11-19 | — | — | US | disclosed |
| EP-3312172-A1 | AMINOPYRAZOLE DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479780-B2 | Aminopyrazole derivatives | SRC, GRK2, GRK3 | ALDH1A1 1534/4885MAPT 3267/4885HPGD 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.